Corporate-Backed Blue Dogs Threaten Democrats’ Budget Plan
Facing health care and climate crises, a group of six conservative House Democrats are seeking to pump the brakes on the largest federal investments in decades.
Page 4
Facing health care and climate crises, a group of six conservative House Democrats are seeking to pump the brakes on the largest federal investments in decades.
Half of lower-income Americans face cost barriers to getting health care, according to a new report from the Commonwealth Fund.
The largest drugmakers spent $56 billion more on stock buybacks and dividends than on research and development from 2016 to 2020, according to a new House committee report.
The plan, initiated by the Trump administration in January, would gut a key government power for making sure taxpayer-funded pharmaceuticals are available to the public at reasonable prices.
A last-minute Trump regulation would eliminate a key government authority that could be used against COVID vaccine price hikes.
An anti-government waste group is helping its Big Pharma funder oppose a discount drug program that doesn’t cost the government a penny.
In states where voters overwhelming approved ballot measures liberalizing marijuana laws, anti-legalization lawmakers and interests are pursuing a range of legal options to thwart the will of voters.
Federal statute instructs judges to disqualify themselves when they have a personal bias concerning a party.
It's the same group that promoted hydroxychloroquine to the president in March.
Center Forward, a "dark money" group with major funding from Big Pharma, is running a Facebook ad campaign touting the pharmaceutical industry as its super PAC spends millions to re-elect Blue Dog Democrats.